The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XVII.b

Opportunistic pulmonary/systemic infections

Publications

Garner O, Ramirez-Berlioz A, Iardino A, Mocherla S, Bhairavarasu K

Disseminated Nocardiosis Associated with Treatment with Infliximab in a Patient with Ulcerative Colitis.

The American journal of case reports. 2017;18:1365-1369

Winthrop KL, Baxter R, Liu L, Varley CD, Curtis JR, Baddley JW, McFarland B, Austin D, Radcliffe L, Suhler E, Choi D, Rosenbaum JT, Herrinton LJ

Mycobacterial diseases and antitumour necrosis factor therapy in USA.

Annals of the rheumatic diseases. 2013;72(1):37-42

Wissmann G, Morilla R, Martín-Garrido I, Friaza V, Respaldiza N, Povedano J, Praena-Fernández JM, Montes-Cano MA, Medrano FJ, Goldani LZ, de la Horra C, Varela JM, Calderón EJ

Pneumocystis jirovecii colonization in patients treated with infliximab.

European journal of clinical investigation. 2011;41(3):343-8

Salmon-Ceron D, Tubach F, Lortholary O, Chosidow O, Bretagne S, Nicolas N, Cuillerier E, Fautrel B, Michelet C, Morel J, Puéchal X, Wendling D, Lemann M, Ravaud P, Mariette X, RATIO group

Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry.

Annals of the rheumatic diseases. 2011;70(4):616-23

Stratakos G, Kalomenidis I, Papas V, Malagari K, Kollintza A, Roussos C, Anagnostopoulou M, Paniara O, Zakynthinos S, Papiris SA

Cough and fever in a female with Crohn's disease receiving infliximab.

The European respiratory journal. 2005;26(2):354-7

Arend SM, Kuijper EJ, Allaart CF, Muller WH, Van Dissel JT

Cavitating pneumonia after treatment with infliximab and prednisone.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology. 2004;23(8):638-41

Hage CA, Wood KL, Winer-Muram HT, Wilson SJ, Sarosi G, Knox KS

Pulmonary cryptococcosis after initiation of anti-tumor necrosis factor-alpha therapy.

Chest. 2003;124(6):2395-7